- Poster presentation
- Open Access
Long-term survival in lung transplant recipients depending on icu length of stay: outcome in a series of 653 consecutive patients
© Zemtsovski et al.; 2015
- Published: 1 October 2015
- Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Pulmonary Hypertension
- Pulmonary Fibrosis
Over the last two decades lung transplantation (LT) has become the treatment of choice for various end-stage lung diseases. It is well-known that the majority of patients who underwent LT experienced complications postoperatively. Postoperative mortality has decreased due to improved surgical techniques and intensive care. However, very little is known about the long-term outcome of lung transplant recipients with prolonged intensive care length of stay (ICU LOS).
To determine long-term survival after LT depending on ICU LOS.
A retrospective review of all patients receiving LT in Denmark in 1992-2014. The population of lung transplant recipients was divided into groups with respect to ICU LOS: 7, 14 and 28 days. Kaplan-Meier analysis was used to compare the overall survival between groups.
Lung transplantation was performed in 653 patients. Single lung transplantation was performed in 330 cases, double lung transplantation in 323 cases. Main indications were chronic obstructive pulmonary disease (n = 272), alpha1-antitrypsin deficiency (n = 141), cystic fibrosis (n = 99), pulmonary fibrosis (n = 67), sarcoidosis (n = 29), primary pulmonary hypertension (n = 14), and other end-stage lung diseases (n = 31).
The median ICU LOS was 3 days with interquartile range 5 and minimum-maximum 0-156 days. The median survival time (MST) for the entire series was 6.1 years.
Of 614 patients who survived the first 28 days after LT, 43 (7%) had ICU LOS more than 28 days. The MST in this group was 1.0 year compared with 7.0 years in the group of patients with ICU LOS ≤ 28 days
A significant number of LT recipients required prolonged ICU LOS postoperatively. The prolonged ICU LOS was associated with poor long-term survival.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.